May 26, 2020 -- Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector (AAV)-based gene therapy drug candidate (LYS-GM101) for the treatment of GM1 gangliosidosis, a neuronopathic lysosomal storage disorder.
Under the agreement, the companies will also consolidate their partnership on the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, which is currently in late-phase clinical trials. Novasep will bring their expertise in manufacturing and production to help Lysogene in clinical development and to shorten the transition to commercial manufacturing.